Advanced Biology, Год журнала: 2025, Номер unknown
Опубликована: Фев. 28, 2025
Abstract The approval of JAK inhibitors, represented by baricitinib, for the treatment alopecia areata (AA) has ushered in a new era. However, their excessive immunosuppressive effects have also raised numerous concerns. Therefore, development inhibitors with different selectivities may enhance drug safety while maintaining therapeutic efficacy. CS12192, developed our team, is selective JAK3 inhibitor that partially inhibits JAK1 and TBK1. In this study, we evaluate effectiveness CS12192 baricitinib C3H/HeJ skin‐transplanted AA mouse model conduct in‐depth analysis similarities differences mechanisms two compounds using mass cytometry (CyTOF) RNA‐seq technology. results show could reverse hair growth inhibition mice dose‐dependent manner, high‐dose group exhibiting comparable to but better safety. Further research revealed both significantly reduced infiltration immune cells, particularly CD8 + T skin animals. CyTOF mechanistic between regulating AA‐related cells signaling pathways. conclusion, as novel inhibitor, holds great potential AA.
Язык: Английский